Latest Breaking News

...in a multitude of capacities.

While we are all suspicious of the brain worm guy and his dangerously illiterate contempt for vaccines, the announcement is typical of many similar announcements over many decades.

All clinical trials compare the standard of care. Many fail on this basis. Some fail based on risk/reward basis. I may have reservations about some rejections; I disagreed with the decision in the 1990s to not approve Omapatrlat, which may have addressed a population, largely African American who did not respond to blood pressure drugs, but I fully recognize that the drug, which cost billions of dollars to develop, had very real risks of death to a subpopulation. (This was during the Clinton administration. ) To be clear, there are a large number of scientists at FDA who are vastly smarter than I am.

I certainly support the development of vaccines, and I am thrilled with the science connected with RNA based approaches. However few people here are qualified to stand in judgement of clinical trial approvals.

This is not an unusual event and the assumption it is political is probably without basis.